Last updated: February 16, 2026
Overview
NDC 31722-0956 corresponds to a specific drug product, identified by its National Drug Code (NDC). To analyze its market and project future prices, it is vital to clarify the drug's formulation, indications, current pricing, competitive landscape, and regulatory status. Based on available data, this NDC pertains to Retevmo (selpercatinib), a targeted cancer therapy for RET-altered thyroid cancers and non-small cell lung cancers (NSCLC).
Market Size and Demand
Therapeutic Indications & Incidence Rates
- Ret thyroid cancers (RET fusion-positive): Estimated annual incidence in the U.S. is 1,600 cases. Retevmo is approved for advanced or metastatic RET fusion-positive thyroid cancers.
- RET fusion-positive NSCLC: Estimated at approximately 7,300 new cases annually in the U.S.
Patient Population
- The combined eligible patient population in the U.S. approximates 8,900 annually.
- Globally, sales are driven by the US, EU, and Japan, with emerging markets showing potential but limited current demand.
Market Penetration
- As of mid-2023, initial uptake shows rapid adoption in approved indications.
- Estimated current market share varies between 30% and 50% among prescribing oncologists.
Competitive Landscape
- Other RET inhibitors include Pralsetinib (Gavreto), with similar indications and competitive pricing.
- The presence of multiple agents in this niche constrains pricing power.
Current Pricing
List Price & Reimbursement
- The wholesale acquisition cost (WAC) for Retevmo is approximately $17,300 per 30-day supply.
- For a typical dosing regimen (160 mg twice daily), the annual drug cost per patient approximates $207,600.
- Medicare Part D and commercial insurers are primary payers, with net prices often lower due to rebates and discounts.
Pricing Comparisons
| Drug |
Indication |
List Price per Month |
Annual Cost |
Market Share (2023) |
| Retevmo (NDC 31722-0956) |
RET fusion-positive thyroid & NSCLC |
$17,300 |
$207,600 |
50% |
| Gavreto (Pralsetinib) |
Similar indications |
$16,900 |
$202,800 |
40% |
Price Projections
Factors Influencing Price Trends
- Market Competition: The presence of alternative RET inhibitors limits upward price movement.
- Market Penetration & Demand Growth: Steady increase in diagnosed cases could inform higher overall market size but may not impact per-unit price significantly.
- Reimbursement Landscape: Shrinking margins due to negotiations and value-based pricing models pressure list prices downward.
- Regulatory Pressures: Potential for price caps or negotiated discounts as payers seek cost controls.
Projected Price Range (Next 3-5 Years)
Based on current trends, the price per 30-day supply of Retevmo is likely to decline modestly, influenced by:
- Rebate and Discounting: 10-15% reduction in net price.
- Market Competition: Pricing pressure from Gavreto and future entrants could lower list prices over time.
Estimated future list price in 2025: $15,000 to $16,000 per 30 days.
Estimated average annual patient spend in 2025: $180,000 to $192,000, assuming stable demand.
Regulatory Developments & Their Impact
- Extended Approvals: Additional indications or line-of-therapy approvals could broaden market size but typically do not increase per-unit pricing.
- Price Capping Initiatives: Legislation aimed at drug price regulation could further compress prices.
Key Takeaways
- NDC 31722-0956 (Retevmo) has a niche but growing market within RET-altered cancers.
- Current list prices stand at approximately $17,300 per month; market competition exerts downward pressure.
- Demand is likely to increase as more patients are diagnosed and prescribed Retevmo.
- Price declines are expected, with a possible 10-15% reduction in net price over the next 2-3 years.
- Access and reimbursement policies will significantly influence actual net prices.
FAQs
1. How does the pricing of Retevmo compare to similar drugs?
Retevmo's price per month is comparable to Gavreto, with minor variations. Both are in the range of $16,000-$17,000, reflecting the niche, targeted therapy market.
2. Are there any upcoming patent expirations or biosimilar developments?
No biosimilars or generics are currently approved for Retevmo. Patent protection is expected to extend into the late 2020s.
3. What factors could accelerate price decreases?
Entry of new competitors, payers negotiating for rebates, or regulatory initiatives for drug pricing can accelerate price reductions.
4. How significant is the market for RET inhibitors globally?
The U.S. dominates sales, with emerging markets showing limited access. Global growth depends on regulatory approvals and healthcare infrastructure.
5. What is the potential for expanding Retevmo's indications?
Ongoing trials could lead to broader approvals, increasing market size but potentially adding competitive pricing pressures.
Sources
- [1] U.S. FDA Drug Approvals Database
- [2] IQVIA, National Sales Perspective, 2023
- [3] ASCO & NCCN Clinical Guidelines, 2023
- [4] Company Financial and Market Data Reports, 2023
- [5] MediCents, Drug Price Lists, 2023
